Not Yet RecruitingNot Applicable

BAG3-DCM Natural History Study

30 participantsStarted 2026-05

Plain-language summary

The goal of this international observational study is to learn about the natural history of Dilated Cardiomyopathy (DCM) arising from pathogenic BAG3 variants in adult patients ≥18 years of age.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Adult patients 18 years or older at the time of providing informed consent (i.e., signing the ICF).
✓. Capable and willing to provide signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and protocol.
✓. Diagnosis of DCM as defined by mild to moderate systolic dysfunction performed within 12 months of enrollment and confirmed by the principal investigator that the DCM is predominantly non-ischemic.
✓. Documentation of a pathogenic or likely pathogenic variant in BAG3 by a CLIA-certified or equivalent genetic testing laboratory.
✓. NYHA class I-III

What they're measuring

Cardiac structure and function

Timeframe: 48 months

Trial details

NCT IDNCT07486752

SponsorRocket Pharmaceuticals Inc.

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2032-12

Contact for this trial

Clinical Information

646-627-0033 clinicaltrials@rocketpharma.com

View on ClinicalTrials.gov More Dilated Cardiomyopathy (DCM) trials